Guizhou Xinbang Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Guizhou Xinbang Pharmaceutical Co., Ltd. Class A carries a market capitalization of 5.07B, placing it among publicly traded companies globally. Its enterprise value stands at 4.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Guizhou Xinbang Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Guizhou Xinbang Pharmaceutical Co., Ltd. Class A has 1.94B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Guizhou Xinbang Pharmaceutical Co., Ltd. Class A maintains a current ratio of 3.62, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Guizhou Xinbang Pharmaceutical Co., Ltd. Class A recorded 27.19M in income tax expense.

As of the close on October 23, 2026, Guizhou Xinbang Pharmaceutical Co., Ltd. Class A's stock has declined approximately 28.75% over the past 52 weeks. The 50-day moving average sits at 3.00, while the 200-day moving average is 3.11.

As of June 30, 2026, Guizhou Xinbang Pharmaceutical Co., Ltd. Class A holds 1.40B in cash and equivalents against 412.40M in total debt, resulting in a net debt position of -1.11B. Total book value stands at 6.75B, with working capital of 3.44B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Guizhou Xinbang Pharmaceutical Co., Ltd. Class A paid dividends of 0.10 per share.

Guizhou Xinbang Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 25, 2015 with a 2:5 split ratio.